Bahamas vs Guyana: Access to anti-retroviral drugs, female
Bahamas
76.0%
in 2024
Guyana
75.0%
in 2024
Bahamas rank
64th
Guyana rank
67th
Access to anti-retroviral drugs, female over time
- Bahamas
- Guyana
How they compare
Bahamas currently reports 76.0% against 75.0% in Guyana, a difference of 1.0%.
The two have swapped places 7 times across 25 shared years of data; in 2000 it was Guyana ahead.
Bahamas ranks 64th and Guyana ranks 67th of 141 countries.
Across the 3 decades both report, Bahamas averaged higher in 2 and Guyana in 1.
Head to head by decade
| Decade | Bahamas | Guyana | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 22.9% | 20.9% | 2.0% | Bahamas |
| 2010s | 58.5% | 66.6% | 8.1% | Guyana |
| 2020s | 74.4% | 72.6% | 1.8% | Bahamas |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Bahamas or Guyana?
- Bahamas, at 76.0% against 75.0% in Guyana as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Bahamas and Guyana?
- 1.0%, with Bahamas ahead.
- How many years of comparable data are there for Bahamas and Guyana?
- 25 years are reported by both, from 2000 to 2024.
- How do Bahamas and Guyana rank globally for access to anti-retroviral drugs, female?
- Bahamas ranks 64th and Guyana ranks 67th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.